Inhibiting the aggregation process of Aβ42 is one of the main objectives in the development of therapies for Alzheimer’s disease, but the heterogeneous nature of the neurotoxic oligomers poses a significant challenge. Researchers from the Universita degli Studi di Firenze presented the preclinical evaluation of DesAb-O, a single-domain antibody targeting Aβ42 oligomers.